|
2024 Journal Article Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registryIrving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Huynh, Kim, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew and McQuilten, Zoe K. (2024). Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLoS One, 19 (8 August) e0308812, e0308812. doi: 10.1371/journal.pone.0308812 |
|
2024 Journal Article Variation in immunoglobulin use and impact on survival in myelomaChai, Khai Li, Wellard, Cameron, Thao, LTP, Aoki, Naomi, Moore, Elizabeth M, Augustson, Bradley M, Bapat, Akshay, Blacklock, Hilary, Chng, Wee J, Cooke, Rachel, Forsyth, Cecily J, Goh, Yeow‐Tee, Hamad, Nada, Harrison, Simon J, Ho, P Joy, Hocking, Jay, Kerridge, Ian, Kim, Jin Seok, Kim, Kihyun, King, Tracy, McCaughan, Georgia J, Mollee, Peter, Morrissey, C Orla, Murphy, Nick, Quach, Hang, Tan, Xuan Ni, Tso, Allison CY, Wong, Kimberly SQ, Yoon, Sung‐Soo ... McQuilten, Zoe K (2024). Variation in immunoglobulin use and impact on survival in myeloma. eJHaem, 5 (4), 690-697. doi: 10.1002/jha2.938 |
|
2024 Journal Article Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapseHo, P. Joy, Spencer, Andrew, Mollee, Peter, Bryant, Christian E., Enjeti, Anoop K., Horvath, Noemi, Butcher, Belinda E., Trotman, Judith, Gibbs, Simon and Joshua, Douglas E. (2024). Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse. Clinical Lymphoma Myeloma and Leukemia, 24 (8), 543-552. doi: 10.1016/j.clml.2024.04.001 |
|
2024 Journal Article Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)Mollee, Peter, Reynolds, John, Janowski, Wojt, Quach, Hang, Campbell, Philip, Gibbs, Simon, Lee, Sophie, Lee, Edwin, Taylor, Kerry, Cochrane, Tara, Wallington-Gates, Craig, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian, Weston, Helen, Ho, P. Joy, Leahy, Michael F, Horvath, Noemi and Spencer, Andrew (2024). Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16). Blood Advances, 8 (14), 3721-3730. doi: 10.1182/bloodadvances.2023012539 |
|
2024 Journal Article The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)Ho, P. Joy, Moore, Elizabeth, Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrrison, Simon J., MacDonald, Emma‐Jane, McQuilten, Zoe K., Wood, Erica M., Mollee, Peter and Spencer, Andrew (2024). The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). British Journal of Haematology, 205 (4), 1337-1345. doi: 10.1111/bjh.19624 |
|
2024 Journal Article Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 studyNinkovic, Slavisa, Harrison, Simon J, Lee, Je-Jung, Murphy, Nick, Lee, Jae Hoon, Estell, Jane, Chen, Vivien M, Horvath, Noemi, Kim, Kihuyn, Eek, Richard, Augustson, Bradley, Bang, Soo-Mee, Huang, Shang-Yi, Rajagopal, Rajeev, Szabo, Ferenc, Engeler, Daniel, Butcher, Belinda E, Mollee, Peter, Durie, Brian, Chng, Wee Joo and Quach, Hang (2024). Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study. Haematologica, 109 (7), 2229-2238. doi: 10.3324/haematol.2023.284238 |
|
2024 Journal Article 2024 Australia–New Zealand Expert Consensus Statement on Cardiac AmyloidosisBart, Nicole K., Fatkin, Diane, Gunton, James, Hare, James L., Korczyk, Dariusz, Kwok, Fiona, Lam, Kaitlyn, Russell, David, Sidiqi, Hasib, Sutton, Tim, Gibbs, Simon D.J., Mollee, Peter and Thomas, Liza (2024). 2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis. Heart, Lung and Circulation, 33 (4), 420-442. doi: 10.1016/j.hlc.2023.11.027 |
|
2024 Journal Article Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?Ranjit Anderson, Nirija, Korczyk, Dariusz and Mollee, Peter (2024). Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?. Expert Review of Hematology, 17 (9), 567-579. doi: 10.1080/17474086.2024.2388184 |
|
2023 Conference Publication Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment AccuracyRanjit Anderson, Nirija, Law, W. Phillip, Dong, Xin, Ng, Arnold C.T and Mollee, Peter (2023). Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186377 |
|
2023 Conference Publication Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)Quach, Hang, Lasica, Masa, Low, Michael, Mollee, Peter, Lai, Hock Choong, Wong Doo, Nicole, Hocking, Jay, Campbell, Philip, Murphy, Nicholas E., Sidiqi, M. Hasib, Routledge, David, Heenan, Jessica, Horvath, Noemi, Eek, Richard, Renwick, William E. P., Lenton, Douglas Stuart, Child, Lauren J, McCaughan, Georgia, Butcher, Belinda E, Mazumdar, Deepmala and Kalff, Anna (2023). Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand). 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-185169 |
|
2023 Conference Publication Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases RegistriesLim, Kenneth J. C., Wellard, Cameron, Moore, Elizabeth, Ninkovic, Slavisa, Chng, Wee-Joo, Spencer, Andrew, Mollee, Peter, Hocking, Jay, Ho, Phoebe Joy, Janowski, Wojt, Kim, Kihyun, Dun, Karen, McQuilten, Zoe K., Chen, Fiona and Quach, Hang (2023). Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-173896 |
|
2023 Conference Publication Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based RegimenChakravorty, Lipi, Gibbons, Anthea, Anderson, Nirija, Kwok, Fiona, Korczyk, Dariusz, Abro, Emad Uddin, Lam, Stephanie, Gibbs, Simon, Mollee, Peter and Sidiqi, M. Hasib (2023). Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186335 |
|
2023 Conference Publication A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple MyelomaTang, Andy, Kim, Kihyun, Chen, Fiona, McQuilten, Zoe K., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Ho, Phoebe Joy, Harrison, Simon J., Spencer, Andrew and Chng, Wee-Joo (2023). A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-178192 |
|
2023 Conference Publication High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLLSabdia, Muhammed B., Burgess, Melinda, Law, Soi Cheng, Thurgood, Lauren A., Kazakoff, Stephen, Swain, Fiona, Tobin, Joshua W.D., Mollee, Peter, Patch, Ann-Marie and Gandhi, Maher K (2023). High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-174149 |
|
2023 Conference Publication Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based ChemotherapyGibbons, Anthea, Ranjit Anderson, Nirija, Chakravorty, Lipi, Kwok, Fiona, Sidiqi, Hasib, Gibbs, Simon, Korczyk, Dariusz, Abro, Emad Uddin and Mollee, Peter (2023). Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-179219 |
|
2023 Journal Article Screening for and diagnosis of monoclonal gammopathyChong, Yuh Ping, Lim, Say Min, Loh, Tze Ping, Mollee, Peter, Wijeratne, Nilika and Choy, Kay Weng (2023). Screening for and diagnosis of monoclonal gammopathy. Journal of Clinical Pathology, 76 (11), 727-733. doi: 10.1136/jcp-2023-208774 |
|
2023 Conference Publication Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational studyAnderson, Nirija Ranjit, Abro, Emad, Korczyk, Dariusz and Mollee, Peter (2023). Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational study. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02060-8 |
|
2023 Conference Publication Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosisAnderson, Nirija Ranjit, Tobin, Joshua, Law, Phillip and Mollee, Peter (2023). Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosis. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02059-1 |
|
2023 Journal Article Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaCass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007 |
|
2023 Conference Publication Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapyMollee, Peter, Gibbons, Anthea, Anderson, Niri Ranjit, Korczyk, Dariusz, Gibbs, Simon and Sidiqi, Hasib (2023). Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02056-6 |
